

REVENIO

Revenio Group Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10

Revenio Group Corporation, Stock Exchange Release, September 1, 2022 at 6.00 p.m. (EEST)

Revenio Group Corporation has received an announcement from William Demant Invest A/S on September 1, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5.

According to the announcement, the total number of Revenio Group Corporation shares owned by William Demant Invest A/S increased to over fifteen (15) per cent of the share capital of Revenio Group Corporation on August 30, 2022.

Total position of William Demant Invest A/S subject to the notification:

	% of shares and voting rights	% of shares and voting rights through financial instruments	% of total	Total number of shares and voting rights in issuer
Resulting situation on the date on which the threshold was crossed or reached	15.10%		15.10%	26,681,116
Position of previous flagging notification (if applicable)	10.17%		10.17%	

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

1. Shares and voting rights

Class / type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights	
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
Fl0009010912	4,028,205		15.10%	

REVENIO

SUBTOTAL	4,028,205	15,10%
-----------------	-----------	--------

For further information, please contact

Robin Pulkkinen, CFO, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

Distribution

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10](#)